We are very happy to announce that we have expanded our team with further experts for formal preclinical and clinical development to propel our way into the clinical stage with our disease modifying lead compound AC102. AudioCure has gained the support of highly...
Reimar Schlingensiepen succeeds Prof. Hans Rommelspacher, the founder of AudioCure, as CEO. Rommelspacher will continue as CSO. AudioCure recently secured funding of about 9 million euros in a Series A financing round from Austrian MED-EL Elektromedizinische...
It is with great pleasure that we announce the relaunch of our corporate brand and website. The brand design has been refined and updated to reflect AudioCure’s innovative and forward-thinking outlook. Meanwhile, we hope that with its clear structure, easy navigation...
AudioCure Pharma GmbH secures funding of about EUR 9 Million for the further development of their lead candidate, AC102, in hearing loss. Austrian company MED-EL Elektromedizinische Geräte GmbH (MED-EL), Innsbruck, the technology leader in implantable hearing...
Following extensive preclinical research, AudioCure Pharma has selected AC102 as its candidate for clinical development. Our next step will be to bring AC102 into the so-called formal preclinical stage of development, a prerequisite for the initiation of clinical...
We are very pleased to announce the start of our collaboration with Dr. Julian Hellmann-Regen, Head of the Clinical Neurobiology Laboratory at the Charité Universitätsmedizin, Berlin. Dr. Hellmann and his team will further investigate the molecular mode of action of...
This website uses cookies. By clicking on the “Ok” button, you consent to our use of cookies as described in our Privacy Notice. If you continue to use this site we will assume that you agree with our Privacy Police.OkRead more
